Lingating, Esterlita .
HRN: 06-81-30 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/28/2024
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
03/28/2024
04/04/2024
IV
1.5gram
Q6
Infected Wound
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes